Trial Profile
Phase I Study of Veliparib (ABT-888) in Combination With Cisplatin Plus Gemcitabine in Advanced Biliary, Pancreatic, Urothelial, and Non-small Cell Lung Cancer.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Cisplatin; Gemcitabine
- Indications Biliary cancer; Non-small cell lung cancer; Pancreatic cancer; Urogenital cancer
- Focus Adverse reactions; Biomarker
- 11 Jul 2012 Planned end date changed from 1 Sep 2011 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 03 Feb 2011 New trial record
- 01 Feb 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.